Edwards Lifesciences (EW) Capital Expenditures (2009 - 2026)

Edwards Lifesciences' Capital Expenditures history runs 18 years deep, the most recent figure standing at $64.9 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 15.89% year-over-year to $64.9 million; the TTM figure through Mar 2026 stood at $269.1 million (up 10.7% YoY), while the FY2025 annual figure was $260.2 million, up 3.09% from the prior year.
• Capital Expenditures was $64.9 million for Q1 2026 at Edwards Lifesciences, down from $97.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $97.4 million in Q4 2025 to a low of $43.1 million in Q2 2022.
• Historically, Capital Expenditures has averaged $63.2 million across 5 years, with a median of $59.9 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures tumbled 43.6% in 2024, then soared 95.58% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $68.9 million in 2022, then grew by 28.16% to $88.3 million in 2023, then sank by 43.6% to $49.8 million in 2024, then jumped by 95.58% to $97.4 million in 2025, then sank by 33.37% to $64.9 million in 2026.
• The last three Capital Expenditures figures came in at $64.9 million (Q1 2026), $97.4 million (Q4 2025), and $57.5 million (Q3 2025), per Business Quant data.